Humatch is a computational antibody humanization tool that transforms non-human (typically murine) antibody variable regions into sequences that resemble human antibodies. Reducing the "foreignness" of therapeutic antibodies is critical for avoiding anti-drug antibody (ADA) responses in patients, but humanization must preserve the original binding specificity encoded in the CDR loops.
What distinguishes Humatch from earlier approaches is that it humanizes heavy and light chains jointly. Most humanization methods treat VH and VL independently, but the pairing of heavy and light chains affects expression, stability, and whether immunogenic epitopes form across the VH/VL interface. Humatch uses three lightweight convolutional neural networks (CNNs) trained on millions of antibody sequences from the Observed Antibody Space (OAS) to guide mutations toward a specific target human V-gene while simultaneously optimizing VH/VL pairing compatibility.
Humatch was developed by Lewis Chinery, Jeliazko R. Jeliazkov, and Charlotte M. Deane at the University of Oxford and GSK R&D.
Humatch trains three CNNs, each with 40 convolutional filters (kernel size 10, stride 1) operating on Kidera factor encodings of aligned antibody sequences:
All three classifiers were trained on data from the OAS database: 8.26 million human and 3.77 million non-human heavy chains, 12.73 million human and 1.41 million non-human light chains, and 1.67 million natural pairs plus 5.01 million artificially mis-paired sequences.
Input sequences are aligned to 200 IMGT-numbered positions using ANARCI, with missing positions filled by gap tokens. For the paired classifier, heavy and light chains are concatenated with a 10-residue pad separator, yielding a 410-position input.
Humanization proceeds in two phases.
Phase 1: Germline-likeness matching. Before engaging the CNNs, the algorithm computes a germline-likeness (GL) score for each chain. At every IMGT position, precomputed amino acid frequency tables for the target V-gene define how "germline-like" each residue is. The mean frequency across all positions gives the GL score. Mutations that maximize GL increase are applied iteratively until the GL score reaches the target threshold (default: 0.40). This initial step places the sequence on a sensible humanization trajectory without requiring expensive CNN inference.
Phase 2: CNN-guided mutation selection. The algorithm then generates all possible single-point variants at non-CDR positions, scores each with all three CNNs, and selects the mutation that best improves CNN scores toward their targets. The selection formula accounts for:
The process repeats until all three CNN scores reach their target thresholds or the maximum number of mutations is exhausted.
Rather than one-hot amino acid encodings (which allowed spurious mutations in testing) or protein language model embeddings (which would bloat model size), Humatch uses 10-dimensional Kidera factor vectors that capture physicochemical properties of each amino acid. Combined with early stopping during training, this produces classifiers that generalize smoothly across sequence space rather than memorizing sharp decision boundaries.
ProteinIQ provides browser-based access to Humatch, running the full humanization pipeline on cloud infrastructure without requiring Python, TensorFlow, or ANARCI installation.
| Input | Description |
|---|---|
Heavy Chain (VH) | Antibody heavy chain variable region sequence. Raw amino acid sequence or FASTA format. Typically ~120 residues. |
Light Chain (VL) | Antibody light chain variable region sequence. Raw amino acid sequence or FASTA format. Typically ~110 residues. |
Both chains are required. Sequences must contain only standard amino acids (20 canonical residues) and must be recognizable as antibody variable domains for IMGT numbering to succeed.
| Setting | Description |
|---|---|
Minimum humanness score | CNN score threshold for accepting a humanized sequence (0.5-0.95, default 0.7). Higher values produce more human-like sequences but may require more mutations. |
Maximum edits per chain | Upper bound on amino acid substitutions per chain (5-50, default 20). Lower values preserve more of the original sequence. |
Preserve CDR regions | When enabled (default), CDR residues are excluded from mutation candidates to maintain antigen-binding specificity. |
| Setting | Description |
|---|---|
Include sequence alignment | Show alignment between original and humanized sequences. |
Include V-gene details | Report the predicted target human V-gene (IGHV/IGLV/IGKV) for each chain. |
Output format | Download format: CSV (default), TSV, or JSON. |
The output table summarizes the humanization outcome for each chain:
| Property | Description |
|---|---|
| Original sequence | The input VH/VL sequence before humanization |
| Humanized sequence | The modified sequence with framework mutations applied |
| Predicted V-gene | The human V-gene family the CNN targets (e.g., HV3, KV1) |
| Humanness score | CNN probability that the sequence belongs to the predicted human V-gene class (0-1) |
| Paired score | CNN-P probability that the VH/VL pair resembles a naturally occurring human pair |
| Edit count | Number of amino acid substitutions relative to the input |
| Score | Range | Interpretation |
|---|---|---|
| Humanness (CNN-H/L) | > 0.95 | High confidence the sequence resembles the target human V-gene |
| Humanness (CNN-H/L) | 0.7 - 0.95 | Moderately human-like; may benefit from additional framework optimization |
| Humanness (CNN-H/L) | < 0.7 | Substantially non-human character remains |
| Paired (CNN-P) | > 0.5 | Pairing resembles natural human VH/VL combinations |
| Paired (CNN-P) | < 0.5 | Pairing may have stability or immunogenicity concerns |
High CNN-P scores correlate with higher melting temperatures in therapeutic antibodies, suggesting paired optimization contributes to developability beyond just immunogenicity.
